Novartis Flags Phase III Remibrutinib MS Data, Plans Investor Call

Novartis AG plans to present late-breaking Phase III REMODEL-1/-2 remibrutinib multiple sclerosis (MS) data, alongside new Kesimpta data, at MSToronto2026. The company will host an investor call following the remibrutinib presentation.